Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
4142-Multiple myeloma KRd (carfilzomib lenalidomide dexamethasone) | eviQ
Design of randomized phase 3 trials. A, ASPIRE trial; B, ENDEAVOR... | Download Scientific Diagram
Carfilzomib for relapsed and refractory multiple myeloma | CMAR
PDF) Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database - McCurdy - 2022 - eJHaem - Wiley Online Library
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma - ScienceDirect
Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect
Aumento della sopravvivenza con carfilzomib per il mieloma multiplo • NCF
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Second Phase 3 Study Shows KYPROLIS Regimen Improves Overall Survival in Patients with Relapsed MM | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
Carfilzomib: new standard of care for myeloma | PPT
ASPIRE Trial - KRd VS Rd - Multiple Myeloma Clinical Trials
Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma | Future Oncology
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma | Blood Cancer Journal
Figure 1 from Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. | Semantic Scholar
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials - Mateos - 2018 -
Carfilzomib - JADPRO
Carfilzomib: new standard of care for myeloma | PPT
KRd Efficacy | KYPROLIS® (carfilzomib)
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia
Carfilzomib è disponibile in Italia per il mieloma multiplo • NCF
